Biomedical Engineering Reference
In-Depth Information
73. Kikuchi, A., Nozawa, T., Wakasawa, T., Maeda, T. and Tamai, I. (2006). Transporter-
mediated intestinal absorption of fexofenadine in rats. Drug Metab Pharmacokinet 21,
308-314.
74. Endres, C.J., Hsiao, P., Chung, F.S. and Unadkat, J.D. (2006). The role of transporters in
drug interactions. Eur J Pharm Sci 27, 501-517.
75. Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H. and Sugiyama, Y. (1998).
Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic
interaction in the liver. Pharmacol Rev 50, 387-412.
76. Shitara, Y., Itoh, T., Sato, H., Li, A.P. and Sugiyama, Y. (2003). Inhibition of transporter-
mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin
and cyclosporin A. J Pharmacol Exp Ther 304, 610-616.
77. Shitara, Y., Sato, H. and Sugiyama, Y. (2005). Evaluation of drug-drug interaction in the
hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol 45, 689-723.
78. Campbell, S.D., de Morais, S.M. and Xu, J.J. (2004). Inhibition of human organic anion
transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia.
Chem Biol Interact 150, 179-187.
79. Horikawa, M., Kato, Y., Tyson, C.A. and Sugiyama, Y. (2002). The potential for an
interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as
a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab
Pharmacokinet 17, 23-33.
80. Horikawa, M., Kato, Y., Tyson, C.A. and Sugiyama, Y. (2003). Potential cholestatic
activity of various therapeutic agents assessed by bile canalicular membrane vesicles
isolated from rats and humans. Drug Metab Pharmacokinet 18, 16-22.
81. Ueda, K., Kato, Y., Komatsu, K. and Sugiyama, Y. (2001). Inhibition of biliary excretion
of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro
data. J Pharmacol Exp Ther 297, 1036-1043.
82. Inotsume, N., Nishimura, M., Nakano, M., Fujiyama, S. and Sato, T. (1990). The inhibitory
effect of probenecid on renal excretion of famotidine in young, healthy volunteers. J Clin
Pharmacol 30, 50-56.
83. Lin, J.H., Los, L.E., Ulm, E.H. and Duggan, D.E. (1988). Kinetic studies on the com-
petition between famotidine and cimetidine in rats: evidence of multiple renal secretory
systems for organic cations. Drug Metab Dispos 16, 52-56.
84. Tahara, H., Kusuhara, H., Endou, H., Koepsell, H., Imaoka, T., Fuse, E. and Sugiyama, Y.
(2005). A species difference in the transport activities of H2 receptor antagonists by rat and
human renal organic anion and cation transporters. J Pharmacol Exp Ther 315, 337-345.
85. Tahara, H., Shono, M., Kusuhara, H., Kinoshita, H., Fuse, E., Takadate, A., Otagiri, M.
and Sugiyama, Y. (2005). Molecular cloning and functional analyses of OAT1 and OAT3
from cynomolgus monkey kidney. Pharm Res 22, 647-660.
86. Tahara, H., Kusuhara, H., Chida, M., Fuse, E. and Sugiyama, Y. (2006). Is the monkey an
appropriate animal model to examine drug-drug interactions involving renal clearance?
Effect of probenecid on the renal elimination of H2 receptor antagonists. J Pharmacol
Exp Ther 316, 1187-1194.
87. Nozaki, Y., Kusuhara, H., Endou, H. and Sugiyama, Y. (2004). Quantitative evaluation
of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory
drugs in the renal uptake process based on the contribution of organic anion transporters
and reduced folate carrier. J Pharmacol Exp Ther 309, 226-234.
Search WWH ::
Custom Search